French pharmaceutical giant Sanofi has announced the acquisition of Blueprint Medicines, a US-based biopharma company specializing in rare immunological diseases, for $9.1 billion. The deal strengthens Sanofi’s immunology pipeline, adding Ayvakit/Ayvakyt (avapritinib)—the only approve...
French pharmaceutical giant Sanofi has announced the acquisition of Blueprint Medicines, a US-based biopharma company specializing in rare immunological diseases, for $9.1 billion. The deal strengthens Sanofi’s immunology pipeline, adding Ayvakit/Ayvakyt (avapritinib)—the only approved treatment for advanced and indolent systemic mastocytosis (ASM & ISM).
Key Highlights:
Strategic Expansion: Sanofi will pay $129 per share in cash, representing a 27.3% premium over Blueprint’s last closing price.
Pipeline Boost: The acquisition includes Elenestinib, a next-generation treatment for systemic mastocytosis, and BLU-808, a promising KIT inhibitor for immunological diseases.
Market Impact: The deal positions Sanofi as a leader in rare immunology, complementing its existing autoimmune and allergy treatments.
Financial Terms: Blueprint shareholders will receive contingent value rights (CVRs), allowing for additional milestone payments based on future drug approvals.
CEO Statement: Sanofi’s CEO Paul Hudson emphasized that the acquisition aligns with the company’s long-term strategy to strengthen its immunology portfolio and deliver innovative treatments.
With this acquisition, Sanofi aims to accelerate its transformation into a global immunology powerhouse, leveraging Blueprint’s expertise and established presence in the field